5 lessons on finding truth in an uncertain world
Adam Kucharski is a professor of epidemiology at the London School of Hygiene & Tropical Medicine and an award-winning science writer. His book, The Rules of Contagion, was a Book of the Year in The Times, Guardian, and Financial Times. A mathematician by training, his work on global outbreaks has included Ebola, Zika, and COVID. He has advised multiple governments and health agencies. His writing has appeared in Wired, Observer, and Financial Times, among other outlets, and he has contributed to several documentaries, including BBC's Horizon.
What's the big idea?
In all arenas of life, there is an endless hunt to find certainty and establish proof. We don't always have the luxury of 'being sure,' and many situations demand decisions be made even when there is insufficient evidence to choose confidently. Every field—from mathematics and tech to law and medicine—has its own methods for proving truth, and what to do when it is out of reach. Professionally and personally, it is important to understand what constitutes proof and how to proceed when facts falter.
Below, Adam shares five key insights from his new book, Proof: The Art and Science of Certainty. Listen to the audio version—read by Adam himself—in the Next Big Idea App.
1. It is dangerous to assume something is self-evident.
In the first draft of the U.S. Declaration of Independence, the Founding Fathers wrote that 'we hold these truths to be sacred and undeniable, that all men are created equal.' But shortly before it was finalized, Benjamin Franklin crossed out the words 'sacred and undeniable,' because they implied divine authority. Instead, he replaced them with the famous line, 'We hold these truths to be self-evident.' The term 'self-evident' was borrowed from mathematics—specifically from Greek geometry. The idea was that there could be a universal truth about equality on which a society could be built.
This idea of self-evident, universal truths had shaped mathematics for millennia. But the assumption ended up causing a lot of problems, both in politics and mathematics. In the 19th century, mathematicians started to notice that certain theorems that had been declared 'intuitively obvious' didn't hold up when we considered things that were infinitely large or infinitely small. It seemed 'self-evident' didn't always mean well-evidenced.
Meanwhile, in the U.S., supporters of slavery were denying what Abraham Lincoln called the national axioms of equality. In the 1850s, Lincoln (himself a keen amateur mathematician) increasingly came to think of equality as a proposition rather than a self-evident truth. It was something that would need to be proven together as a country. Similarly, mathematicians during this period would move away from assumptions that things were obvious and instead work to find sturdier ground.
2. In practice, proof means balancing too much belief and too much skepticism.
If we want to get closer to the truth, there are two errors we must avoid: we don't want to believe things that are false, and we don't want to discount things that are true. It's a challenge that comes up throughout life. But where should we set the bar for evidence? If we're overly skeptical and set it too high, we'll ignore valid claims. But if we set the bar too low, we'll end up accepting many things that aren't true.
In the 1760s, the English legal scholar William Blackstone argued that we should work particularly hard to avoid wrongful convictions. As he put it: 'It is better that ten guilty persons escape than that one innocent suffer.' Benjamin Franklin would later be even more cautious. He suggested that 'it is better 100 guilty persons should escape than that one innocent person should suffer.'
'We don't want to believe things that are false, and we don't want to discount things that are true.'
But not all societies have agreed with this balance. Some communist regimes in the 20th century declared it better to kill a hundred innocent people than let one truly guilty person walk free.
Science and medicine have also developed their own traditions around setting the bar for evidence. Clinical trials are typically designed in a way that penalizes a false positive four times more than a false negative. In other words, we don't want to say a treatment doesn't work when it does, but we really don't want to conclude it works when it doesn't.
This ability to converge on a shared reality, even if occasionally flawed, is fundamental for science and medicine. It's also an essential component of democracy and justice. Rather than embracing or shunning everything we see, we must find ways to balance the risk that comes with trusting something to be true.
3. Life is full of 'weak evidence' problems.
Science is dedicated to generating results that we can have high confidence in. But often in life, we must make choices without the luxury of extremely strong evidence. We can't, as some early statisticians did, simply remain on the fence if we're not confident either way. Whether we're sitting on a jury or in a boardroom, we face situations where a decision must be made regardless.
This is known as the 'weak evidence' problem. For example, it might be very unlikely that a death is just a coincidence. But it also might be very unlikely that a certain person is a murderer. Legal cases are often decided on the basis that weak evidence in favor of the prosecution is more convincing than weak evidence for the defendant.
Unfortunately, it can be easy to misinterpret weak evidence. A prominent example is the prosecutor's fallacy. This is a situation where people assume that if it's very unlikely a particular set of events occurred purely by coincidence, that must mean the defendant is very unlikely to be innocent. But to work out the probability of innocence, we can't just focus on the chances of a coincidence. What really matters is whether a guilty explanation is more likely than an innocent one. To navigate law—and life—we must often choose between unlikely explanations, rather than waiting for certainty.
4. Predictions are easier than taking action.
If we spot a pattern in data, it can help us make predictions. If ice cream sales increase next month, it's reasonable to predict that heatstroke cases will too. These kinds of patterns can be useful if we want to make predictions, but they're less useful if we want to intervene in some way. The correlation in the data doesn't mean that ice cream causes heatstroke, and crucially, it doesn't tell us how to prevent further illness.
'Often in life, prediction isn't what we really care about.'
In science, many problems are framed as prediction tasks because, fundamentally, it's easier than untangling cause and effect. In the field of social psychology, researchers use data to try to predict relationship outcomes. In the world of justice, courts use algorithms to predict whether someone will reoffend. But often in life, prediction isn't what we really care about. Whether we're talking about relationships or crimes, we don't just want to know what is likely to happen—we want to know why it happened and what we can do about it. In short, we need to get at the causes of what we're seeing, rather than settling for predictions.
5. Technology is changing our concept of proof.
In 1976, two mathematicians announced the first-ever computer-aided proof. Their discovery meant that, for the first time in history, the mathematical community had to accept a major theorem that they could not verify by hand.
However, not everyone initially believed the proof. Maybe the computer had made an error somewhere? Suddenly, mathematicians no longer had total intellectual control; they had to trust a machine. But then something curious happened. While older researchers had been skeptical, younger mathematicians took the opposite view. Why would they trust hundreds of pages of handwritten and hand-checked calculations? Surely a computer would be more accurate, right?
Technology is challenging how we view science and proof. In 2024, we saw the AI algorithm AlphaFold make a Nobel Prize-winning discovery in biology. AlphaFold can predict protein structures and their interactions in a way that humans would never have been able to. But these predictions don't necessarily come with traditional biological understanding.
Among many scientists, I've noticed a sense of loss when it comes to AI. For people trained in theory and explanation, crunching possibilities with a machine doesn't feel like familiar science. It may even feel like cheating or a placeholder for a better, neater solution that we've yet to find. And yet, there is also an acceptance that this is a valuable new route to knowledge, and the fresh ideas and discoveries it can bring.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
39 minutes ago
- Medscape
Fast Five Quiz: How Much Do You Know About Bell Palsy?
Bell palsy, or idiopathic facial paralysis, is the most common peripheral paralysis of the facial nerve (cranial nerve VII). Many cases of facial nerve paralysis have identifiable etiologies, such as stroke, Lyme disease, or Ramsay Hunt syndrome, but Bell palsy is, by definition, idiopathic in nature. How much do you know about Bell palsy and its management? Check your knowledge with this quick quiz. Type 2 diabetes is associated with several types of peripheral neuropathy, including Bell palsy. The prevalence of peripheral neuropathy among patients with type 2 diabetes has been calculated to be as high as 53.6%. In one retrospective cohort study, 33% of participants with Bell palsy had coexisting type 2 diabetes. Additionally, obesity might increase the risk for Bell palsy. Some studies have concluded that there is a slight female preponderance among patients with Bell palsy, whereas others have found no sex predilection. Even if female sex is not a risk factor, evidence suggests that Bell palsy is associated with pregnancy. The median age of onset is 40 years, and patient age < 15 years is not a risk factor. However, Bell palsy has been identified in children and even infants. Facial nerve trauma can certainly cause symptoms resembling Bell palsy, but Bell palsy is idiopathic and does not have a traumatic etiology. If these symptoms resulted from trauma, the diagnosis would be traumatic facial nerve palsy rather than Bell palsy. Learn more about Bell palsy epidemiology. Lagophthalmos, but not true eyelid ptosis, is a characteristic feature of Bell palsy. Symptoms of Bell palsy typically have a rapid onset, manifesting from 24 to 72 hours and often resolving or partially resolving within a few weeks to 3 months. In Bell palsy, facial paralysis is usually unilateral, and bilateral facial paralysis should lead to consideration and evaluation for other etiologies. Hearing loss is not a typical symptom of Bell palsy. The presence of hearing loss indicates an association with an upper motor neuron lesion or a lesion involving more than the facial nerve. Learn more about Bell palsy presentation. A rapid evidence review on Bell palsy points out that, as the condition is idiopathic, laboratory diagnostics are not required for a diagnosis. Clinical practice guidelines from the American Academy of Otolaryngology-Head and Neck Surgery concur that diagnostic testing is not needed to identify Bell palsy. The guidelines recommend that clinicians should not obtain routine laboratory testing in patients with new-onset Bell palsy, pointing out that this approach is not cost-effective. However, both the rapid evidence review and guidelines state that laboratory testing can help identify systemic causes of facial palsy symptoms, such as Lyme disease or diabetes, when reasonable clinical suspicion exists. Learn more about workup for Bell palsy. Oral corticosteroids are recommended in a rapid evidence review as the first-line treatment for Bell palsy. Guidelines from the American Academy of Otolaryngology-Head and Neck Surgery also recommend this approach in patients age = 16 years with Bell palsy. Antiviral monotherapy has not been demonstrated to influence recovery and should be avoided. However, combination therapy with oral corticosteroids and antivirals should be considered, as this approach consistently results in lower rates of synkinesis and might reduce rates of incomplete recovery. Local injectable anesthetic would not be an appropriate therapy because it would not address the underlying cause, lower motor neuron palsy. There is no evidence-based role for local anesthetic in the treatment of Bell palsy. Electroconvulsive therapy is mostly used in the treatment of severe mood disorders. The mechanism of action would not be expected to be useful in the treatment of facial nerve palsy. Learn more about management of Bell palsy. Along with the Sunnybrook facial grading system, the House-Brackmann scale is widely used to qualify symptom severity of Bell palsy. A patient with obvious facial weakness, inability to move the forehead, incomplete closure of the eyelids, and mouth asymmetry with maximal effort would be grade IV, moderately severe symptoms. Grade I is classified as a normal presentation with full facial function in all areas. Grade II is characterized by slight facial weakness on close inspection, slight synkinesis, and no lagophthalmos. Grade III would exhibit moderate symptoms with noticeable, but not severe, synkinesis; obvious facial asymmetry but not disfiguring; complete eyelid closure with effort; and slightly weak mouth even with maximal effort. Learn more about Bell palsy prognosis.
Yahoo
an hour ago
- Yahoo
Northallerton group wins award for raising £13k in memory of Cliffy
Family and friends of a Northallerton man who died after a battle with Huntington's Disease have won an award for their fundraising efforts. The group, who have been raising money in memory of Cliffy Jack, were honoured with the Huntington's Disease Association Fundraising Group of the Year Award. Mr Jack passed away at the age of 71 in June 2022 after 16 years of battling the disease. The condition progressively affects nerve cells in the brain, impacting movement, cognitive functions, and emotions. Cliffy Jack (Image: Family) In his memory, Mr Jack requested family and friends participate in 'Cliffy's Challenge'. The challenge aimed to raise awareness about the devastating effects of Huntington's Disease and gather funds for the Huntington's Disease Association. Their fundraising activities have included a skydive, a charity golf day, the Great North Run, loom band making, a raffle, a sponsored swim, and a musical evening. Cliffy's Challenge (Image: Family) A 'Celebrate Cliffy' event in September at the Golden Lion Hotel in Northallerton drew 250 attendees, raising £6,000 through ticket sales and a raffle. The group has collectively raised more than £13,000 to date. Upcoming efforts include a 24-hour football-athon and a 50-mile coastal walk. For more information on how to support or participate in Cliffy's Challenge, visit
Yahoo
an hour ago
- Yahoo
Altum Sequencing develops tool to monitor solid tumour treatment response
Cancer cell monitoring startup Altum Sequencing has developed a tool that uses a simple blood sample for monitoring treatment response in individuals with solid tumours. The company is based in the C3N-IA Science Park at Universidad Carlos III de Madrid (UC3M), Spain. According to the university, the study detailed the tool's effectiveness, highlighting that although many individuals with hormone receptor+ (HR+) breast cancer respond well initially, there is a relapse rate of up to 40%. By utilising the developed technology and examining circulating tumour DNA, researchers have succeeded in predicting the occurrence of clinical relapses as much as 68 months earlier than what conventional methods could reveal. The process for the early detection of relapses starts with obtaining an initial tumour biopsy. From this sample, patient-specific mutations are determined. Subsequently, blood tests are analysed for the presence of these specific mutations in the circulating tumour DNA. This approach is not limited to breast cancer; it is applicable to any solid tumour type, and researchers are seeking regulatory approvals in the US and Europe to make it globally accessible. Altum Sequencing president Joaquín Martínez-López said: 'Our goal is not to diagnose cancer, but to provide physicians with an effective tool to monitor the evolution of the disease after treatment. 'Current diagnostic tools have sensitivity limitations, which makes early detection of these relapses difficult, but thanks to NGS (next generation sequencing) DNA sequencing technology, we can detect one tumour cell among a million healthy cells from a simple blood sample.' The startup is also exploring the integration of generative AI. It has already incorporated machine learning algorithms and now aims to utilise this new technology to further enhance its diagnostic processes. The company has received backing from the Community of Madrid, the Centre for Technological Development and Innovation, and the European Regional Development Fund. It is also partnering with hospitals and research centres, including the Gregorio Marañón Hospital and Universidad Complutense. "Altum Sequencing develops tool to monitor solid tumour treatment response" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
